Utah Medical Products, Inc. — Q1 2024 Form 10-Q
Business context and period: The company manufactures and markets specialty medical devices. This unaudited report covers the three months ended March 31, 2024; comparative figures are for Q1 2023. Unless noted, financial amounts below are in U.S. dollars.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $11.340 million | $12.520 million | Down 9.4% |
| Gross profit / margin | $6.766 million / 59.7% | $7.843 million / 62.6% | Profit down 13.7% |
| Operating income / margin | $3.883 million / 34.2% | $4.439 million / 35.5% | Down 12.5% |
| Income before tax | $4.798 million | $5.119 million | Down 6.3% |
| Net income / margin | $3.956 million / 34.9% | $4.214 million / 33.7% | Down 6.1% |
| Diluted EPS | $1.09 | $1.16 | Down 5.7% |
| Operating cash flow | $5.276 million | $6.915 million | Down $1.639 million |
Other income was $915,000 versus $680,000, mainly reflecting higher interest income. The effective tax rate was 17.6%, compared with 17.7%. Adjusted EBITDA, a non-GAAP measure defined by the company, was $5.547 million versus $6.919 million.
Balance sheet and capital allocation
- At March 31, cash and investments were $93.808 million, total assets $135.441 million, and stockholders’ equity $127.742 million. Cash and investments were $92.868 million at year-end 2023.
- The company reported no debt. Total liabilities were $7.699 million; the current ratio was 19.6, versus 22.6 at December 31, 2023.
- Q1 financing cash outflows included $2.990 million for repurchases and $1.089 million in dividends. The company repurchased 43,108 shares at an average $69.37 per share.
- After quarter-end through May 3, the company repurchased another 63,985 shares for $4.323 million, averaging $67.57 per share.
Material changes and management commentary
- Sales fell primarily because worldwide sales to the largest OEM customer declined $1.046 million year over year. Management said this customer moved sensor manufacturing in-house and that no new orders had been received in 2024.
- Domestic sales declined 14%; sales outside the U.S. declined 3% as reported, or 4% in constant currency. The largest OEM customer’s sales are included in Blood Pressure Monitoring and Accessories, whose worldwide sales fell to $3.212 million from $4.150 million.
- Gross margin weakened because manufacturing overhead did not decline as quickly as sales; favorable product mix and improved direct labor productivity partly offset the pressure. Management expects a greater percentage decline in full-year gross profit as it anticipates further revenue declines and persistent overhead.
- Operating expenses were lower year over year, partly because the $1.105 million Q1 2023 amortization of the CSI Filshie intangible asset ended after October 2023. Higher litigation costs and R&D spending partly offset that benefit. R&D spending increased for testing and certification of pressure sensors for biopharma manufacturing.
- Filshie device sales in the U.S. fell 15.6%; management said misinformation on social media related to unresolved product-liability lawsuits seemed to be having a negative effect.
Outlook, risks and contingencies
- Management said Q1 results were consistent with its 2024 projections, which anticipate progressively weaker results through the rest of the year. Assuming no new orders from the largest OEM customer, management expects its sales to be lower year over year by $1.7 million in Q2, $2.0 million in Q3, and $1.8 million in Q4.
- The largest Chinese distributor of blood-pressure-monitoring devices postponed Q4 2024 shipments; the comparable Q4 2023 revenue was $1.2 million.
- Management’s stated priorities include developing high-pressure process-control transducers for biopharma manufacturers, expanding product development and international operating synergies, defending the Filshie system, and pursuing acquisitions where attractive. It expects to use excess cash for investment, dividends, or repurchases depending on opportunities and share value.
- Filshie clip product-liability lawsuits remained in discovery. The company said it did not expect their outcome to be material to consolidated results. It reported no other current or threatened litigation, apart from matters incidental to business.
- Foreign-exchange movements are a risk; the company said it does not use separate hedging transactions. Management reported disclosure controls were effective and no material internal-control changes during the quarter.
Important facts for investors to verify
- Whether the largest OEM customer resumes orders, and how its projected sales reductions affect revenue, utilization, and gross margin.
- Whether the postponed China distributor shipments occur and whether other customer or supply-chain issues affect sales.
- Trends in manufacturing overhead absorption, gross margin, and operating expenses as revenue declines.
- Developments in Filshie litigation and any impact on sales, litigation expense, or liabilities.
- The pace and price of subsequent share repurchases, alongside cash use for dividends, investment, or acquisitions.